ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022: Lintuzumab-Ac225 in Combination With Intensive Chemo Yields High Response Rate and MRD Negativity in R/R AML With Adverse Features
By
ASH 2022 Conference Coverage
FEATURING
Sameem Abedin
By
ASH 2022 Conference Coverage
FEATURING
Sameem Abedin
41 views
December 28, 2022
Login to view comments.
Click here to Login
Leukemia